SoftOx Solutions AS hereby announces that the Company has secured commitments
from selected shareholders to participate in a guarantee-consortium for a
planned contemplated right issue. A majority of the shareholders participate in
the guarantee-consortium. This planned contemplated right issue of NOK 22,5
million with a subscription price of NOK 0,02 will provide the company
sufficient funding to plan, prepare, and run a process aiming to attract funding
for a proof-of-concept, human phase 2 clinical trial for treatment of
Ventilator-Associated Pneumonia (VAP). 

The Board of Directors has unanimously approved the agreement and will call for
an extraordinary General Meeting by the end of July 2024 to seek approval of the
contemplated right share issue and the guarantee-agreement with selected
shareholders. The contemplated right issue will be executed by the 24th of
August 2024. 

The planned share issue will give equal rights for all shareholders to
participate. It will be a right issue with transferable subscription rights.
Each shareholder will be issued rights to subscribe for their pro-rata amount of
shares in the issue. The rights will be made tradable. Subscription of Shares
that are not subscribed for, according to rights, will be granted to guarantees
before others. If the Share Issue is over-subscribed, the participants in the
agreement are granted the first right to subscribe for shares in the Share
Issue.   

 

For further information, please contact:   

Geir Almås, COB or Ingrid Juven, CFO of SoftOx Solutions AS, or   

Mail: ir@soft-ox.com   

Phone: Geir Almås, COB: (+47) 977 59 071   



About SoftOx Solutions AS:   

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a
Norwegian MedTech/biotech company based in Oslo with the aim of helping to
combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses. For more information on SoftOx, visit www.soft-ox.com